In the paper by Stolz et al. 1, bosentan deteriorated not only exercise capacity but also hypoxaemia and quality of life among subjects with severe or very severe chronic obstructive pulmonary disease (COPD). While the concept of a new drug category which could improve functional status among these patients is challenging, the theoretical background …